Global Circulating Tumor Cell (CTC) Diagnostics Market to Grow 9.39% CAGR to 2021 – Analysis of ApoCell, Qiagen, and Menarini Silicon Biosystems

MarketResearchNest.com adds “Global Circulating Tumor Cell (CTC) Diagnostics Market 2017-2021” new reports to its research database. The report spread across 67 pages with tables and figures in it.

The research analysts forecast the global circulating tumor cell (CTC) diagnostics market to grow at a CAGR of 9.39% during the period 2017-2021.

Cancer is diagnosed by blood count, bone marrow biopsy, and molecular identification of mutated cells. CTC diagnostics helps in the identification of deoxyribonucleic acid (DNA) shed by tumor cells. CTCs are cancerous cells which detach from primary tumor and migrate in the bloodstream or lymphatic system of the patient. CTCs in the blood or lymphatic system helps in providing important information regarding prognosis and treatment effectiveness for cancer patients.

Get more details about report at https://www.marketresearchnest.com/global-circulating-tumor-cell-ctc-diagnostics-market-2017-2021.html .

Technavio recognizes the following companies as the key players in the global circulating tumor cell (CTC) diagnostics market: ApoCell, Qiagen, and Menarini Silicon Biosystems.

Other Prominent Vendors in the market are: Advanced Cell Diagnostics, BioCep, BIOCEPT, BioFluidica, Celltraffix, Clearbridge Biomedics, Creatv MicroTech, Cynvenio, Epic Sciences, Fluxion Biosciences, Gilupi, Ikonisys, IVDiagnostics, and ScreenCell.

One trend in the market is introduction of advanced detection technologies. Cancer is a lethal disease taking toll across the geographical regions. The use of advanced technologies has helped in early diagnosis of cancer and improved treatment in patients. Diagnostic imaging technology has introduced molecular imaging technique for the detection of cancerous cells.

Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=267817 . (This is premium report, Single User License – USD 3500 and Corporate User License – USD 6000)

According to the report, one driver in the market is increasing incidences of cancer. Cancer is one of the lethal diseases, which has increased mortality rate worldwide. Various types of cancer occur due to genetic changes, high consumption of alcohol, smoking, and other lifestyle changes. The overall burden of cancer is increasing across the globe. Some of the most common type of cancers are breast cancer, colon cancer, prostate cancer, lung and bronchus cancer, kidney cancer, pancreatic cancer, leukemia, and melanoma of skin.

Further, the report states that one challenge in the market is high cost of diagnostics. Cancer treatment covers the majority of healthcare expenditure in most of the countries across the world. Cancer drug expenditure is also increasing in the countries. The treatment and diagnosis cost of cancer cases such as leukemia, multiple myeloma, and lymphoma is high compared to the treatment and prognosis of pancreatic, melanoma, and thyroid cancer. In developed countries such as the US, Medicare covers about 60%-80% of the treatment and diagnosis cost for cancer cases. With the availability of POC detection for cancer diagnosis, the overall cost of diagnosis increases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Inquire before buying this report at https://www.marketresearchnest.com/enquirybuy.php?reportid=267817 .

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

This release was published on openPR.